InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies.
+ 1 more risk
Flawless balance sheet and overvalued.
Share Price & News
How has InMed Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MWG2's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MWG2 underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: MWG2 underperformed the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is InMed Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StMarket Sentiment Around Loss-Making InMed Pharmaceuticals Inc (FRA:MWG2)
1 year ago | Simply Wall StInMed Pharmaceuticals Inc's (FRA:MWG2) Earnings Dropped -137.44%, How Did It Fare Against The Industry?
2 years ago | Simply Wall StWho Are InMed Pharmaceuticals Inc's (FRA:MWG2) Major Shareholders?
Is InMed Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MWG2's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MWG2's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MWG2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MWG2 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MWG2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MWG2 is good value based on its PB Ratio (3.4x) compared to the DE Biotechs industry average (3.6x).
How is InMed Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MWG2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MWG2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MWG2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MWG2's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if MWG2's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MWG2's Return on Equity is forecast to be high in 3 years time
How has InMed Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MWG2 is currently unprofitable.
Growing Profit Margin: MWG2 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MWG2 is unprofitable, and losses have increased over the past 5 years at a rate of -35.9% per year.
Accelerating Growth: Unable to compare MWG2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MWG2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: MWG2 has a negative Return on Equity (-120.01%), as it is currently unprofitable.
How is InMed Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MWG2's short term assets (CA$12.4M) exceed its short term liabilities (CA$1.7M).
Long Term Liabilities: MWG2's short term assets (CA$12.4M) exceed its long term liabilities (CA$386.2K).
Debt to Equity History and Analysis
Debt Level: MWG2 is debt free.
Reducing Debt: MWG2 has no debt compared to 5 years ago when its debt to equity ratio was 24%.
Inventory Level: MWG2 has a low level of unsold assets or inventory.
Debt Coverage by Assets: MWG2's debt is covered by short term assets (assets are 2.2289905227245E+17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MWG2 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MWG2 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -45.3% each year.
What is InMed Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MWG2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MWG2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MWG2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MWG2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MWG2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Adams (56yo)
Mr. Eric A. Adams, B.S. Chem., M.I.B. has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences ...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD552.90K) is about average for companies of similar size in the German market ($USD432.27K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
|Senior Vice President of Preclinical Research & Development||1.17yrs||CA$294.01k||0.024% CA$6.5k|
|Co-Founder & Member of the Scientific Advisory Board||1.17yrs||CA$184.70k||no data|
|Chief Financial Officer||0.58yr||no data||0.029% CA$7.7k|
|Director of Investor Relations||no data||no data||no data|
|Vice President of Sales & Marketing||15.5yrs||no data||no data|
|Senior Vice President of Clinical & Regulatory Affairs||3.42yrs||CA$692.50k||0.12% CA$30.8k|
|Senior Consultant of Medical Affairs||no data||no data||no data|
Experienced Management: MWG2's management team is considered experienced (3.4 years average tenure).
|Co-Founder & Member of the Scientific Advisory Board||1.17yrs||CA$184.70k||no data|
|Member of Scientific Advisory Board||1yr||no data||no data|
|Independent Chairman of the Board||no data||CA$98.17k||no data|
|Independent Director||3.5yrs||CA$65.07k||0.36% CA$96.1k|
|Independent Director||4.33yrs||CA$65.07k||no data|
|Independent Director||0.67yr||no data||no data|
|Member of Scientific Advisory Board||2.42yrs||no data||no data|
|Member of Scientific Advisory Board||1.83yrs||no data||no data|
Experienced Board: MWG2's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.2%.
InMed Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: InMed Pharmaceuticals Inc.
- Ticker: MWG2
- Exchange: DB
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$41.348m
- Listing Market Cap: CA$26.498m
- Shares outstanding: 172.28m
- Website: https://www.inmedpharma.com
Number of Employees
- InMed Pharmaceuticals Inc.
- 815West Hastings Street
- Suite 310
- British Columbia
- V6C 1B4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IN||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Aug 1999|
|MWG2||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Aug 1999|
|IMLF.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Aug 1999|
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, pulmonary disease, neurodegenerative, and oncology disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-755; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 21:00|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.